HOME >> MEDICINE >> NEWS
ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting

RICHMOND, CALIF. (Monday, May 18, 1998) --- Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX) today reported results from two Phase II studies of its lead anticancer viral therapeutic, ONYX-015, in patients with tumors of the head and neck. In an ongoing Phase II study combining ONYX-015 with standard chemotherapy, the company reported that nine out of ten patients with recurrent tumors have experienced tumor regressions of greater than 50 percent to date, with two patients experiencing complete responses. In addition, the company reported that 30 percent of patients treated with ONYX-015 alone had significant tumor regressions, including two complete regressions in patients with end-stage, treatment-resistant disease.

During a poster session today at the American Society of Clinical Oncology (ASCO) meeting in Los Angeles, Onyx presented interim results from a Phase II trial combining ONYX-015 with Cisplatin and 5-FU, two standard chemotherapeutic agents used in the treatment of head and neck cancers. In addition to the two patients who had complete responses, seven patients experienced between 50 and 95 percent reductions in tumor mass. The one remaining patient has experienced a 40 percent tumor regression. To date, all of the patients continue on treatment with no evidence of disease progression. The average overall response rate with Cisplatin and 5-FU alone is about 35 percent historically in patients with recurrent disease,noted David H. Kirn, M.D., director of clinical research at Onyx.

"We have seen significant tumor regression in the patients treated to date, including some complete responses, and this is a dramatic early finding," Dr. Kirn said. "But we have only evaluated ten patients at this point. While we are encouraged by these initial results, we remain cautiously optimistic."

"Of course, because this is an ongoing study, we do not yet have information regarding durability of responses. We will be able to discuss these findings with gre
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415/ 821-2413
Kureczka/Martin Associates
18-May-1998


Page: 1 2 3

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
5. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
6. Pharmaceuticals and personal care products
7. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
8. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
9. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... ... February 19, 2019 , ... In one ... pregnant and postpartum women, a team led by a Worcester Polytechnic Institute professor ... show increased depressive symptoms, greater weight gain during pregnancy, and weight retention after ...
(Date:2/19/2019)... ... February 19, 2019 , ... Pneumatic Vacuum Elevators, LLC ... provide information on how-to make a house handicap accessible. , With this ... make a house handicap accessible. To accurately educate consumers on handicap accessibility, ...
(Date:2/19/2019)... ... February 19, 2019 , ... Hospice of Westchester (HOW) ... The funds will support the heart of its operation, the organization’s Home Care Services. ... years, and we are grateful for their ongoing generosity,” said Mary K. Spengler, MS, ...
(Date:2/19/2019)... ... 2019 , ... The California Dental Association is pleased to ... as a new member benefit. , Student loan debt is one of ... all indebted graduates in the class of 2018 for public and private dental ...
(Date:2/19/2019)... YORK (PRWEB) , ... February 19, 2019 , ... ... Dave,” a cancer survivor and well-respected advocate for patient engagement, will deliver the ... Business Conference. deBronkart brings critical awareness of participatory medicine and empowering partnerships between ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... ... , ... Mothers’ Milk Bank of North Texas (MMBNT) has moved ... for the nonprofit. , The building in southwest Fort Worth features three times the ... health and survival of premature and critically ill infants through the safe provision of ...
(Date:2/19/2019)... ... , ... John M. Memory, Ph.D., J.D. , is the author of ... in a University or College Course” (published by Archway Publishing). Memory has concluded that ... undergraduate courses of a major university in the U.S. Southeast. Memory contends these conclusions ...
(Date:2/19/2019)... ... 2019 , ... As one of Delaware’s most-esteemed living artists, fine-arts painter Rick Phillips ... paint, it’s not work,” he said. “You get that feeling in your belly, this is ... Fine art has also given the former commercial artist a serenity and fulfilment he hopes ...
Breaking Medicine Technology:
Cached News: